{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:56:34Z","timestamp":1789959394944,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004320","name":"Philips","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004320","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.esmoop.2024.102383","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T12:53:24Z","timestamp":1708001604000},"page":"102383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6478-7821","authenticated-orcid":false,"given":"J.S.W.","family":"Borgers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5774-675X","authenticated-orcid":false,"given":"A.W.","family":"van Schijndel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.V.","family":"van Thienen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Klobuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.T.P.","family":"Seijkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3890-4534","authenticated-orcid":false,"given":"R.P.","family":"Tobin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"van Heerebeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Driessen-Waaijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.W.","family":"Rohaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.B.A.G.","family":"Haanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.esmoop.2024.102383_bib1","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2024.102383_bib2","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat Med"},{"issue":"25","key":"10.1016\/j.esmoop.2024.102383_bib3","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.esmoop.2024.102383_bib4","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/annonc\/mdz398","article-title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis","volume":"30","author":"Dafni","year":"2019","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2024.102383_bib5","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ncponc0666","article-title":"Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?","volume":"3","author":"Muranski","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102383_bib6","article-title":"Cyclophosphamide-induced cardiomyopathy: a case report, review, and recommendations for management","volume":"1","author":"Dhesi","year":"2013","journal-title":"J\u00a0Investig Med High Impact Case Rep"},{"issue":"7","key":"10.1016\/j.esmoop.2024.102383_bib7","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.1991.9.7.1215","article-title":"Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens","volume":"9","author":"Braverman","year":"1991","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.102383_bib8","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/archinte.1981.00340060066015","article-title":"Cardiotoxicity associated with high-dose cyclophosphamide therapy","volume":"141","author":"Gottdiener","year":"1981","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102383_bib9","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0749-0704(05)70196-2","article-title":"Acute life-threatening toxicity of cancer treatment","volume":"17","author":"Shanholtz","year":"2001","journal-title":"Crit Care Clin"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102383_bib10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.bmt.1703132","article-title":"Serum cardiac troponin I levels and ECG\/Echo monitoring in breast cancer patients undergoing high-dose (7 g\/m(2)) cyclophosphamide","volume":"28","author":"Morandi","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"17","key":"10.1016\/j.esmoop.2024.102383_bib11","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1158\/1078-0432.CCR-13-0380","article-title":"Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies","volume":"19","author":"Besser","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.esmoop.2024.102383_bib12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000070964","article-title":"Monitoring hyperhydration during high-dose chemotherapy: body weight or fluid balance?","volume":"109","author":"Mank","year":"2003","journal-title":"Acta Haematol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102383_bib13","first-page":"218","article-title":"Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity","volume":"79","author":"Spriano","year":"1994","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.esmoop.2024.102383_bib14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/sj.bmt.1704166","article-title":"Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies","volume":"32","author":"Van Besien","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102383_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/sj.bmt.1703098","article-title":"Acute left ventricular failure following melphalan and fludarabine conditioning","volume":"28","author":"Ritchie","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102383_bib16","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1046\/j.1365-2141.2001.03153.x","article-title":"Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study","volume":"115","author":"Martino","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.esmoop.2024.102383_bib17","series-title":"FDAITCS","first-page":"208","article-title":"Perry MC","author":"Gutheil","year":"2001"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102383_bib18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jccase.2019.05.001","article-title":"Persistent heart failure following melphalan and fludarabine conditioning","volume":"20","author":"Newbery","year":"2019","journal-title":"J\u00a0Cardiol Cases"},{"issue":"5","key":"10.1016\/j.esmoop.2024.102383_bib19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jaccao.2022.07.014","article-title":"Cardiotoxicity of T-Cell antineoplastic therapies","volume":"4","author":"Ganatra","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"26","key":"10.1016\/j.esmoop.2024.102383_bib20","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.esmoop.2024.102383_bib21","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.esmoop.2024.102383_bib22","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"10.1016\/j.esmoop.2024.102383_bib23","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.esmoop.2024.102383_bib24","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/j.jacc.2019.10.049","article-title":"Chimeric antigen receptor T-cell therapy for cancer and heart: JACC council perspectives","volume":"74","author":"Ganatra","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.esmoop.2024.102383_bib25","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","article-title":"Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-hodgkin lymphoma","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"issue":"9404","key":"10.1016\/j.esmoop.2024.102383_bib26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(03)15326-3","article-title":"Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock","volume":"363","author":"Pathan","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2024.102383_bib27","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.3389\/fphys.2018.01866","article-title":"Cardiolipotoxicity, inflammation, and arrhythmias: role for interleukin-6 molecular mechanisms","volume":"9","author":"Al\u00ed","year":"2018","journal-title":"Front Physiol"},{"issue":"11","key":"10.1016\/j.esmoop.2024.102383_bib28","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.120.315894","article-title":"Mechanisms of cardiovascular toxicities associated with immunotherapies","volume":"128","author":"Baik","year":"2021","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.esmoop.2024.102383_bib29","first-page":"86","article-title":"Cardiovascular toxicity and mortality associated with adoptive cell therapy and tumor-infiltrating lymphocytes for advanced stage melanoma","volume":"44","author":"Fradley","year":"2021","journal-title":"J\u00a0Immunother (Hagerstown, Md : 1997)"},{"issue":"10","key":"10.1016\/j.esmoop.2024.102383_bib30","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.102383_bib31","article-title":"Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma","volume":"9","author":"Saberian","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2024.102383_bib32","article-title":"Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up","volume":"8","author":"van den Berg","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"8","key":"10.1016\/j.esmoop.2024.102383_bib33","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s00262-020-02572-1","article-title":"Tumor infiltrating lymphocytes as adjuvant treatment in stage III melanoma patients with only one invaded lymph node after complete resection: results from a multicentre, randomized clinical phase III trial","volume":"69","author":"Khammari","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.esmoop.2024.102383_bib34","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.esmoop.2024.102383_bib35","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/nri3156","article-title":"The role of interleukin-2 during homeostasis and activation of the immune system","volume":"12","author":"Boyman","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"5769","key":"10.1016\/j.esmoop.2024.102383_bib36","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1126\/science.1122927","article-title":"Selective stimulation of T cell subsets with antibody-cytokine immune complexes","volume":"311","author":"Boyman","year":"2006","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.esmoop.2024.102383_bib37","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.102383_bib38","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/cncr.23552","article-title":"High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006","volume":"113","author":"Klapper","year":"2008","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.esmoop.2024.102383_bib39","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","article-title":"Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2","volume":"86","author":"Rosenberg","year":"1994","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.esmoop.2024.102383_bib40","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1080\/14740338.2017.1382472","article-title":"High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions","volume":"16","author":"Marabondo","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"41","key":"10.1016\/j.esmoop.2024.102383_bib42","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.esmoop.2024.102383_bib43","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.recesp.2020.11.014","article-title":"Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC","volume":"74","author":"Mart\u00edn Garc\u00eda","year":"2021","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"11","key":"10.1016\/j.esmoop.2024.102383_bib44","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/annonc\/mdw315","article-title":"Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study","volume":"27","author":"Furlanetto","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.102383_bib45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1634\/theoncologist.2014-0187","article-title":"Chemotherapy dose adjustment for obese patients undergoing hematopoietic stem cell transplantation: a survey on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"20","author":"Shem-Tov","year":"2015","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.esmoop.2024.102383_bib46","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.bbmt.2014.01.019","article-title":"Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation Practice Guideline Committee","volume":"20","author":"Bubalo","year":"2014","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924001510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924001510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:32:38Z","timestamp":1761856358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924001510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2059702924001510"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102383","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.102383","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"102383"}}